Literature DB >> 34371036

MyD88: At the heart of inflammatory signaling and cardiovascular disease.

Abraham L Bayer1, Pilar Alcaide2.   

Abstract

Cardiovascular disease is a leading cause of death worldwide and is associated with systemic inflammation. In depth study of the cell-specific signaling mechanisms mediating the inflammatory response is vital to improving anti-inflammatory therapies that reduce mortality and morbidity. Cellular damage in the cardiovascular system results in the release of damage associated molecular patterns (DAMPs), also known as "alarmins," which activate myeloid cells through the adaptor protein myeloid differentiation primary response 88 (MyD88). MyD88 is broadly expressed in most cell types of the immune and cardiovascular systems, and its role often differs in a cardiovascular disease context and cell specific manner. Herein we review what is known about MyD88 in the setting of a variety of cardiovascular diseases, discussing cell specific functions and the relative contributions of MyD88-dependent vs. independent alarmin triggered inflammatory signaling. The widespread involvement of these pathways in cardiovascular disease, and their largely unexplored complexity, sets the stage for future in depth mechanistic studies that may place MyD88 in both immune and non-immune cell types as an attractive target for therapeutic intervention in cardiovascular disease.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alarmin signaling; Cardiovascular disease; Inflammation; MyD88

Mesh:

Substances:

Year:  2021        PMID: 34371036      PMCID: PMC8629847          DOI: 10.1016/j.yjmcc.2021.08.001

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  138 in total

1.  MicroRNA-214 promotes the calcification of human aortic valve interstitial cells through the acceleration of inflammatory reactions with activated MyD88/NF-κB signaling.

Authors:  Dongdong Zheng; Yue Zang; Haixia Xu; Yan Wang; Xiang Cao; Teng Wang; Min Pan; Jiahai Shi; Xiaofei Li
Journal:  Clin Res Cardiol       Date:  2018-12-05       Impact factor: 5.460

2.  Simvastatin down-regulates osteogenic response in cultured human aortic valve interstitial cells.

Authors:  Michael J Jarrett; Qingzhou Yao; Neil Venardos; Michael J Weyant; T Brett Reece; Xianzhong Meng; David A Fullerton
Journal:  J Thorac Cardiovasc Surg       Date:  2019-10-31       Impact factor: 5.209

3.  TLR4 (Toll-Like Receptor 4)-Dependent Signaling Drives Extracellular Catabolism of LDL (Low-Density Lipoprotein) Aggregates.

Authors:  Rajesh K Singh; Abigail S Haka; Arky Asmal; Valéria C Barbosa-Lorenzi; Inna Grosheva; Harvey F Chin; Yuquan Xiong; Timothy Hla; Frederick R Maxfield
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-10-10       Impact factor: 8.311

4.  A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses.

Authors:  Tamas Bartfai; M Margarita Behrens; Svetlana Gaidarova; Janell Pemberton; Alexander Shivanyuk; Julius Rebek
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-10       Impact factor: 11.205

5.  Up-regulated TLR4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction.

Authors:  Li Liu; Yin Wang; Zhi-Yong Cao; Meng-Meng Wang; Xue-Mei Liu; Ting Gao; Qi-Kuan Hu; Wen-Jun Yuan; Li Lin
Journal:  J Cell Mol Med       Date:  2015-08-20       Impact factor: 5.310

6.  IL-1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis.

Authors:  M Gorelik; Y Lee; M Abe; T Andrews; L Davis; J Patterson; S Chen; T R Crother; G J Aune; M Noval Rivas; M Arditi
Journal:  Clin Exp Immunol       Date:  2019-06-21       Impact factor: 4.330

7.  Compound LM9, a novel MyD88 inhibitor, efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy.

Authors:  Xu-Yong Zheng; Chu-Chu Sun; Qian Liu; Xiao-Yao Lu; Li-Li Fu; Guang Liang; Xiu-Hua Zhang; Gao-Zhi Chen
Journal:  Acta Pharmacol Sin       Date:  2020-04-27       Impact factor: 6.150

8.  Macrophages Facilitate Electrical Conduction in the Heart.

Authors:  Maarten Hulsmans; Sebastian Clauss; Ling Xiao; Aaron D Aguirre; Kevin R King; Alan Hanley; William J Hucker; Eike M Wülfers; Gunnar Seemann; Gabriel Courties; Yoshiko Iwamoto; Yuan Sun; Andrej J Savol; Hendrik B Sager; Kory J Lavine; Gregory A Fishbein; Diane E Capen; Nicolas Da Silva; Lucile Miquerol; Hiroko Wakimoto; Christine E Seidman; Jonathan G Seidman; Ruslan I Sadreyev; Kamila Naxerova; Richard N Mitchell; Dennis Brown; Peter Libby; Ralph Weissleder; Filip K Swirski; Peter Kohl; Claudio Vinegoni; David J Milan; Patrick T Ellinor; Matthias Nahrendorf
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

9.  Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection.

Authors:  Martin J Richer; Danielle J Lavallée; Iryna Shanina; Marc S Horwitz
Journal:  PLoS One       Date:  2009-01-05       Impact factor: 3.240

Review 10.  Recent clinical trends in Toll-like receptor targeting therapeutics.

Authors:  Muhammad Ayaz Anwar; Masaud Shah; Jason Kim; Sangdun Choi
Journal:  Med Res Rev       Date:  2018-11-18       Impact factor: 12.944

View more
  2 in total

Review 1.  Inflammation and atherosclerosis: signaling pathways and therapeutic intervention.

Authors:  Peng Kong; Zi-Yang Cui; Xiao-Fu Huang; Dan-Dan Zhang; Rui-Juan Guo; Mei Han
Journal:  Signal Transduct Target Ther       Date:  2022-04-22

2.  Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways.

Authors:  Vincenzo Quagliariello; Margherita Passariello; Annabella Di Mauro; Ciro Cipullo; Andrea Paccone; Antonio Barbieri; Giuseppe Palma; Antonio Luciano; Simona Buccolo; Irma Bisceglia; Maria Laura Canale; Giuseppina Gallucci; Alessandro Inno; Claudia De Lorenzo; Nicola Maurea
Journal:  Front Cardiovasc Med       Date:  2022-09-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.